10-Q · May 15, 2026
Lightwave Logic, Inc. reported increased licensing and royalty revenue for Q1 2026, totaling $29.17 million, a 27.4% rise from $22.92 million in Q1 2025. The company's net loss grew 34% to $6.30 million due to rising…
Earnings analysis · 10-Q
LWLG earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Lightwave Logic’s Q2 revenue increased 28% year over year to $32,751 and gross margin reached 100%, but the revenue base remains very small relative to a $7,301,891 quarterly operating expense base. Net loss widened 33%…
Read full summary
Lightwave Logic’s Q2 revenue increased 28% year over year to $32,751 and gross margin reached 100%, but the revenue base remains very small relative to a $7,301,891 quarterly operating expense base. Net loss widened 33% year over year to $6,613,797, while first-half operating cash use increased to $9,882,537. Liquidity is strong at $95,910,962 of cash and marketable securities with no debt, but management still expects no significant high-volume commercial production revenue until 2027 at the earliest and is funding operations primarily through equity issuance.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Reported figures
- Segment
- Licensing and royalty revenue: $32,751 in Q2 2026, versus $25,605 in Q2 2025 and $29,167 in Q1 2026. No separately reported operating segments.
What stood out
-
Revenue Growth Accelerated
Q2 revenue increased to $32,751 from $25,605 in Q2 2025, a 28% year-over-year increase, and from $29,167 in Q1 2026, a 12% sequential increase. Six-month revenue was $61,918 versus $48,522 in the prior-year period, up 28%.
-
Gross Margin Reached 100%
Gross margin improved to 100.0% in Q2 2026 because cost of sales was $0, versus 86.5% in Q2 2025 when cost of sales was $3,463.
-
Strong Liquidity Position
Cash and cash equivalents were $47,209,148 and marketable securities were $48,701,814 at June 30, 2026, providing $95,910,962 of cash and liquid investments. Management stated these resources should fund operations at least through December 2027.
-
Debt-Free Balance Sheet
The company reported no debt to service at June 30, 2026. Total liabilities were $3,855,523 against total assets of $108,078,889 and stockholders’ equity of $104,223,366.
-
Substantial Equity Funding
Financing activities provided $38,555,054 in the first six months, including $27,883,978 from the Roth Capital ATM agreement, $6,946,686 from option exercises, and $4,930,928 from the Titan offering over-allotment.
-
Investment Supports Commercialization
Operating cash use was $9,882,537 in the first six months, while investing cash use included $1,518,336 for facility and laboratory assets and $245,398 for intangibles. Capital spending and intangible additions totaled $1,763,734, or approximately 18% of operating cash use.
What to watch
-
Losses Continue to Widen
Q2 net loss increased 33% to $6,613,797 from $4,966,633 in Q2 2025. Six-month net loss rose 34% to $12,914,337 from $9,663,657.
-
Rapid Operating Expense Growth
Quarterly operating expenses increased 48% to $7,301,891, including research and development expense of $3,878,703, up 48%, and general and administrative expense of $3,423,188, up 49%. Management expects substantial R&D expenses to continue increasing.
-
Commercial Revenue Remains Deferred
Management does not expect significant revenue from high-volume commercial production until 2027 at the earliest. The Design Win Cycle typically spans approximately 18 to 24 months, and advancement through development stages does not assure commercial production.
-
Cash Burn Outpaces Revenue
Operating cash use increased to $9,882,537 for the first six months of 2026 from $7,260,222 in the prior-year period, a 36% increase, despite only $61,918 of six-month revenue.
-
Equity Financing and Dilution Risk
The company relies heavily on equity financing: first-half 2026 financing inflows totaled $38,555,054, including $27,883,978 from the ATM program. Only $3,385 remained available under the Roth Sales Agreement as of the filing date, creating potential future funding and dilution risk.
-
Customer Adoption and Execution Risk
Commercial production depends on customer qualification, yield validation, manufacturing readiness, end-market demand, and foundry capacity. The filing states there can be no assurance that development programs will transition to volume production or that projected timelines will be achieved.
Management's outlook
No numeric revenue or EPS guidance was provided. Management anticipates that 2026 revenue, if any, will primarily come from material supply, NRE arrangements, or prototype and development activities, and does not expect significant high-volume commercial production revenue until 2027 at the earliest. Management expects existing funding sources and commercial operations to finance the business at least through December 2027.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.